|Name/Company||Approval Dates and Comments|
The French regulatory authority approved this
retinoid in October 2008 for the treatment of severe
chronic refractory hand eczema unresponsive
to potent topical corticosteroids in adults. Also
approved by the Danish Medicines Agency in
September 2008. Marketing applications for
this product are also under review in Canada and
The US FDA approved this solution for intravenous
injection in October 2008 for the treatment of
patients with persistent or recurrent cutaneous
T-cell lymphoma whose malignant cells express the
CD25 component of the IL-2 receptor (CD25+).
The US FDA approved this ophthalmic solution in
Dec 2008 as a novel treatment for hypotrichosis of
the upper eyelashes.
The US FDA approved this CCR5 antagonist in
November 2008 for use in treatment-experienced
adults with CCR5-tropic HIV-1 in combination
with other antiretroviral agents.
1.2% + Benzoyl Peroxide
The US FDA approved this fixed combination
antibiotic and benzoyl peroxide formulation in
November 2008 for the once daily treatment of both
non-inflammatory and inflammatory acne lesions
in patients 12 years of age and older.
The European Medicines Agency (EMEA)
approved this product in January 2009 for the
treatment of chronic severe plaque psoriasis in
children aged 8 years and above.